Your browser doesn't support javascript.
loading
Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
Li, Haifeng; Ni, Mengqian; Xue, Cong; Li, Lu; Huang, Riqing; Yang, Wei; Hu, Anqi; An, Xin; Shi, Yanxia.
Affiliation
  • Li H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Ni M; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Xue C; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Li L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Huang R; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Yang W; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • Hu A; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China.
  • An X; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address: anxin@sysucc.o
  • Shi Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, PR China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address: shiyx@sysucc.o
Clin Immunol ; 236: 108927, 2022 03.
Article in En | MEDLINE | ID: mdl-35031491
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Lung Neoplasms Type of study: Clinical_trials / Systematic_reviews Limits: Female / Humans / Male Language: En Journal: Clin Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2022 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Lung Neoplasms Type of study: Clinical_trials / Systematic_reviews Limits: Female / Humans / Male Language: En Journal: Clin Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2022 Document type: Article Country of publication: Estados Unidos